Table 2 Correlations between the clinical features of different treatment modalities with ORR and PFS
First-line(n = 132) | n | CR | PR | SD | PD | ORR(%) | DCR(%) | Median PFS (months) | P |
|---|---|---|---|---|---|---|---|---|---|
Treatment pattern | |||||||||
 A1 | 25 | 0 | 7 | 15 | 3 | 28.0 | 88.0 | 9.8 | 0.689 |
 A2 | 82 | 0 | 34 | 45 | 3 | 41.5 | 96.3 | 11.4 |  |
 A3 | 11 | 0 | 4 | 6 | 1 | 36.4 | 90.9 | 10.2 |  |
 A4 | 14 | 0 | 6 | 7 | 1 | 42.9 | 92.9 | 16.1 |  |
Efficacy | |||||||||
 2-cycle | 132 | 0 | 51 | 73 | 8 | 38.6 | 93.9 | 11.40 |  |
 4-cycle | 85 | 0 | 38 | 41 | 6 | 44.7 | 92.9 |  |  |
Histology | |||||||||
 Adenocarcinoma | 69 | 0 | 27 | 39 | 3 | 39.1 | 95.7 | 11.4 | 0.839 |
 Squamous cell carcinoma | 63 | 0 | 24 | 34 | 5 | 38.1 | 92.1 | 10 |  |
Mutational status | |||||||||
 EGFR | 28 | 0 | 10 | 16 | 2 | 35.7 | 92.9 | 12.0 | 0.767 |
 ALK | 5 | 0 | 2 | 3 | 0 | 40.0 | 100 | not reached |  |
 Negative | 26 | 0 | 12 | 12 | 2 | 46.2 | 92.3 | 16.0 |  |
 Unknown | 73 | 0 | 27 | 42 | 4 | 40.0 | 94.5 | 9.9 |  |
PD-L1 expression levels | |||||||||
 <1% | 38 | 0 | 11 | 21 | 6 | 28.9 | 84.2 | 6.0 | 0.000 |
 1–49% | 36 | 0 | 14 | 20 | 2 | 38.9 | 94.4 | 12 |  |
  ≥ 50% | 28 | 0 | 17 | 11 | 0 | 60.7 | 100 | not reached |  |
 Unknown | 30 | 0 | 9 | 21 | 0 | 30.0 | 100 | 10.3 |  |
Corticosteroid interference | |||||||||
 Yes | 5 | 0 | 3 | 1 | 1 | 60.0 | 80.0 | not reached | 0.281 |
 No | 127 | 0 | 48 | 72 | 7 | 37.8 | 94.5 | 11.4 |  |
Abx treatment | |||||||||
 Yes(≥7 days) | 21 | 0 | 5 | 11 | 5 | 23.8 | 76.2 | 4 | 0.000 |
 Yes(<7 days) | 19 | 0 | 7 | 12 | 0 | 36.8 | 100 | not reached |  |
 No | 92 | 0 | 39 | 50 | 3 | 42.4 | 96.7 | 13.6 |  |
Immune drugs in NSCLC | |||||||||
 atezolizumab | 6 | 0 | 3 | 3 | 0 | 50.0 | 100 | 9.0 | 0.188 |
 durvalumab | 3 | 0 | 2 | 1 | 0 | 66.7 | 100 | not reached |  |
 sintilimab | 41 | 0 | 14 | 27 | 0 | 34.1 | 100 | 9.1 |  |
 pembrolizumab | 18 | 0 | 9 | 8 | 1 | 50.0 | 94.4 | 16.0 |  |
 camrelizumab | 17 | 0 | 5 | 8 | 4 | 29.4 | 76.5 | 8.3 |  |
 tislelizumab | 33 | 0 | 14 | 17 | 2 | 42.4 | 93.9 | 10.0 |  |
 toripalimab | 14 | 0 | 4 | 9 | 1 | 28.6 | 92.9 | 11.4 |  |
Second-line(n = 113) | |||||||||
Treatment pattern | |||||||||
 B1 | 17 | 0 | 6 | 10 | 1 | 35.3 | 94.1 | 8.0 | 0.283 |
 B2 | 43 | 0 | 12 | 29 | 2 | 27.9 | 95.3 | 15.0 |  |
 B3 | 30 | 0 | 13 | 14 | 3 | 43.3 | 90.0 | 8.5 |  |
 B4 | 23 | 0 | 5 | 16 | 2 | 21.7 | 91.3 | 10.8 |  |
Efficacy | |||||||||
 2-cycle | 113 | 0 | 36 | 69 | 8 | 31.9 | 92.9 | 10.0 |  |
 4-cycle | 71 | 0 | 13 | 50 | 8 | 18.3 | 88.7 |  |  |
Histology | |||||||||
 Adenocarcinoma | 64 | 0 | 19 | 38 | 7 | 29.7 | 89.1 | 10 | 0.117 |
 Squamous cell carcinoma | 49 | 0 | 17 | 31 | 1 | 34.7 | 98.0 | 18.1 |  |
Mutational status | |||||||||
 EGFR | 24 | 0 | 5 | 15 | 4 | 20.8 | 83.3 | 8.5 | 0.356 |
 ALK | 8 | 0 | 5 | 3 | 0 | 62.5 | 100 | 6.3 |  |
 Negative | 43 | 0 | 11 | 29 | 3 | 25.6 | 93.0 | 12.7 |  |
 Unknown | 38 | 0 | 15 | 22 | 1 | 39.5 | 97.4 | 10 |  |
PD-L1 expression levels | |||||||||
 <1% | 39 | 0 | 13 | 21 | 5 | 33.3 | 87.2 | 6.4 | 0.001 |
 1–49% | 26 | 0 | 3 | 22 | 1 | 11.5 | 96.2 | 13.4 |  |
  ≥ 50% | 27 | 0 | 12 | 14 | 1 | 44.4 | 96.3 | not reached |  |
 Unknown | 21 | 0 | 8 | 12 | 1 | 31.0 | 96.6 | 6.4 |  |
Corticosteroid interference | |||||||||
 Yes | 3 | 0 | 2 | 1 | 0 | 66.7 | 100 | 4.5 | 0.025 |
 No | 110 | 0 | 34 | 68 | 8 | 30.9 | 92.7 | 10.8 |  |
Abx treatment | |||||||||
 Yes(≥7 days) | 14 | 0 | 4 | 8 | 2 | 28.6 | 85.7 | 6 | 0.002 |
 Yes(<7 days) | 18 | 0 | 6 | 12 | 0 | 33.3 | 100 | not reached |  |
 No | 81 | 0 | 26 | 49 | 6 | 32.1 | 92.6 | 10.8 |  |
Immune drugs in NSCLC | |||||||||
 atezolizumab | 6 | 0 | 2 | 4 | 0 | 33.3 | 100 | 8.0 | 0.830 |
 durvalumab | 5 | 0 | 0 | 5 | 0 | 0 | 100 | 9.7 |  |
 sintilimab | 45 | 0 | 14 | 29 | 2 | 31.1 | 95.6 | 13.4 |  |
 pembrolizumab | 13 | 0 | 9 | 3 | 1 | 69.2 | 92.3 | 10.0 |  |
 camrelizumab | 16 | 0 | 1 | 14 | 1 | 6.3 | 93.8 | 12.7 |  |
 tislelizumab | 15 | 0 | 3 | 11 | 1 | 20.0 | 93.3 | not reached |  |
 toripalimab | 13 | 0 | 7 | 3 | 3 | 53.8 | 76.9 | 8.5 |  |